APA citáció

Mahaffey Kenneth W., Jardine Meg J., Bompoint Severine, Cannon Christopher P., Neal Bruce, Heerspink Hiddo J.L, . . . et al. (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial.

Chicago Style (17th ed.) Citation

Mahaffey Kenneth W., et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial. 2019.

MLA idézés

Mahaffey Kenneth W., et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial. 2019.